SCHEMBL30396159

SCHEMBL30396159

O=C(O)c1cc2c(OC3CC3)cc(Cl)cc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 11/20 0.60
GRIN1 Q05586 3/20 0.59
MEN1 O00255 2/20 0.48
CYP2C9 P11712 2/20 0.48
HPGD P15428 2/20 0.48
BLM P54132 2/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
MAPK1 P28482 1/20 0.48
GRIN2D O15399 2/20 0.47
GRIN3B O60391 2/20 0.47
GRIN2A Q12879 2/20 0.47
GRIN2B Q13224 2/20 0.47
GRIN2C Q14957 2/20 0.47
GRIN3A Q8TCU5 2/20 0.47
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24190633 1.00 RHEB (0.60) RHEBGRIN1MEN1CYP2C9HPGD
SCHEMBL30396548 0.85 ULK1 (0.48) RHEBGRIN1HPGDKDM4ECYP1A2
SCHEMBL24190632 0.85 ULK1 (0.48) RHEBGRIN1HPGDKDM4ECYP1A2
SCHEMBL24020641 0.81 RHEB (0.64) RHEBGRIN1MEN1CYP2C9HPGD
SCHEMBL30304202 0.80 RHEB (0.60) RHEBGRIN1MEN1CYP2C9HPGD
SCHEMBL28589604 0.78 SRD5A2 (0.40) RHEBGRIN1HPGDKMT2AKDM4E
SCHEMBL20536067 0.76 RHEB (0.81) RHEBGRIN1MEN1CYP2C9HPGD
SCHEMBL20536377 0.75 RHEB (1.00) RHEBGRIN1MEN1CYP2C9HPGD
SCHEMBL29531428 0.75 GRIN1 (1.00) RHEBGRIN1MEN1CYP2C9HPGD
SCHEMBL727389 0.75 GRIN1 (1.00) RHEBGRIN1MEN1CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4165037-A1 ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS Aligos Therapeutics, Inc. (US) 2023-04-19 EP disclosed